

Claim 30 has been canceled without prejudice in order to expedite prosecution of this application. Entry of the claims as amended is respectfully requested.

Claim 11 stands rejected under 35 U.S.C. §112, first paragraph, as allegedly containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains to make or use the invention with regard to pF1V. Applicants are in the process of depositing plasmid pF1-V for patent purposes and will provide the deposit information as soon as it is in hand.

Claim 30 stands rejected under 35 U.S.C. §103(a) as allegedly obvious over WO95/18231 (Titball et al. -'31) and further in view of: WO 95/24475 (Titball et al. -'75); or Leary et al. *Infection and Immunity* **63**: 2854-2858, 1995). This rejection is moot in view of the canceled claim. Applicants acknowledge the withdrawal of the rejection with respect to claim 1-3 and 5-17.

All objections and rejections have been addressed. This application is believed to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

By *S. Pratt, Reg. No. 39,441*
Elizabeth Arwine
Reg. No. 45,867

U.S. A. MPMC
504 Scott Street
Fort Detrick, MD 21702-5012
ATTN: MCMR SGRD-JA (Elizabeth Arwine - Patent Atty)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the

Commissioner of Patents
Washington, D.C. 20231

on April 4, 2003.

By *S. Pratt*
Sana A. Pratt
Reg. No. 39,441